Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Santa Maria › NPI 1447244256
Physician

Lags Spine and Sportscare Medical Centers INC

Lags Spine and Sportscare Medical Centers INC was paid $33.42M by Medicaid between Jan 2018 and May 2021, across 105 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 20% of everything it billed.

33Billing provider infoLAGS SPINE AND SPORTSCARE MEDICAL CENTERS INC
SANTA MARIA, CA 93454
33aNPI1447244256assigned 09/07/2005
28Total paid$33.42M
24GClaims984,179
24DCodes billed105
24AFirst – last monthJan 2018 – May 2021
Compared with peers

Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in California

Rank by total paid#1 of 70
Median peer was paid$39K
This provider vs. median867×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$500K$1.0M$1.5M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018307,862$9.24M
2019316,245$12.06M
2020285,389$9.50M
202174,683$2.63M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 20% 250,429 232,853 $6.56M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 17% 46,324 44,877 $5.53M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 9.4% 73,518 66,893 $3.14M
88356 5.5% 13,096 8,757 $1.83M
95886 4.0% 16,941 16,301 $1.33M
99490 Ccm add 20min 3.9% 76,554 76,024 $1.30M
88360 3.6% 7,887 7,829 $1.21M
64493 2.9% 15,025 7,753 $978K
88305 Level IV - Surgical pathology, gross and microscopic examination 2.5% 8,852 8,772 $824K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.5% 47,854 46,730 $819K
95911 2.2% 8,412 8,312 $742K
88319 2.1% 7,948 7,891 $717K
93 more codes
64483 1.8% 8,967 $610K
64635 1.6% 4,792 $540K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1.5% 4,698 $511K
88314 1.5% 8,819 $508K
95913 1.4% 3,553 $466K
99204 Doctor's office visit, new patient (more involved) 1.4% 9,882 $465K
Q3014 Telehealth originating site facility fee 1.1% 19,289 $378K
96138 <1% 24,608 $327K
64494 <1% 14,045 $291K
64636 <1% 4,716 $288K
99205 Prolong outpt/office vis <1% 1,636 $262K
J3490 Unclassified drugs <1% 25,502 $262K
99203 Doctor's office visit, new patient (routine) <1% 5,965 $258K
90833 Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) <1% 7,370 $235K
64490 <1% 2,898 $230K
11104 <1% 4,185 $227K
64484 <1% 3,532 $187K
20611 <1% 8,007 $176K
99000 <1% 97,068 $156K
11105 <1% 4,144 $132K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 10,835 $125K
96103 <1% 11,284 $115K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 1,880 $112K
64495 <1% 5,056 $111K
76942 <1% 3,952 $107K
90792 Psychiatric diagnostic evaluation with medical services <1% 952 $105K
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 8,146 $67K
95910 <1% 941 $67K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 7,287 $67K
11100 <1% 2,622 $63K
64491 <1% 2,639 $62K
64633 <1% 392 $61K
20553 <1% 1,347 $61K
95912 <1% 489 $59K
64479 <1% 643 $57K
T1014 Telehealth transmission, per minute, professional services bill separately <1% 18,245 $55K
99152 <1% 10,651 $53K
11101 <1% 2,572 $52K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 5,312 $51K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 5,174 $38K
64634 <1% 381 $38K
J1040 Injection, methylprednisolone acetate, 80 mg <1% 4,145 $37K
90834 Psychotherapy session, about 45 minutes <1% 1,170 $37K
95924 <1% 529 $37K
80306 <1% 1,272 $30K
99406 <1% 8,848 $29K
27096 <1% 119 $27K
88341 <1% 575 $26K
88342 <1% 575 $23K
99442 <1% 1,380 $19K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 1,183 $18K
20526 <1% 462 $17K
64492 <1% 695 $15K
99487 Ccm add 20min <1% 102 $11K
99443 <1% 650 $9K
80305 <1% 1,027 $8K
97026 <1% 3,161 $8K
64480 <1% 80 $6K
99243 <1% 173 $6K
97813 <1% 4,212 $6K
97814 <1% 4,207 $6K
20552 <1% 152 $4K
96127 <1% 2,604 $3K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 322 $3K
20610 <1% 46 $2K
76882 <1% 78 $2K
J3300 Injection, triamcinolone acetonide, preservative free, 1 mg <1% 238 $1K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 52 $915.96
95909 <1% 16 $904.33
90837 Psychotherapy session, about an hour <1% 78 $888.39
95923 <1% 298 $800.00
J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose <1% 21 $768.34
99489 Ccm add 20min <1% 15 $759.90
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 35 $682.86
81025 <1% 357 $561.88
95908 <1% 52 $528.86
11721 <1% 47 $278.32
99407 <1% 14 $263.11
62323 <1% 33 $220.03
99441 <1% 66 $193.37
95957 <1% 25 $104.71
11720 <1% 14 $54.52
97124 <1% 2,631 $43.76
97016 <1% 2,169 $8.86
G8431 Screening for depression is documented as being positive and a follow-up plan is documented 0% 329 $0.00
97810 0% 2,003 $0.00
76881 0% 53 $0.00
63650 0% 13 $0.00
G8510 Screening for depression is documented as negative, a follow-up plan is not required 0% 354 $0.00
92285 0% 37 $0.00
3079F 0% 54 $0.00
3075F 0% 55 $0.00
92250 0% 37 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLAGATTUTA, FRANCIS (PRESIDENT)
Same official

Other billing entities under LAGATTUTA, FRANCIS

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.